- Home
- DPRO vs BCYC Comparison
DPRO vs BCYC Comparison
Compare DPRO & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DPRO | BCYC |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | Canada | United Kingdom |
| Employees | N/A | 288 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.6M | 279.9M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DPRO | BCYC |
|---|---|---|
| Price | $5.02 | $4.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $15.00 | $13.90 |
| AVG Volume (30 Days) | ★ 2.1M | 573.1K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $158.69 | N/A |
| Revenue Next Year | $131.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.96 | $3.92 |
| 52 Week High | $14.37 | $9.18 |
Technical Indicators
Market Signals| Indicator | DPRO | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 46.55 |
| Support Level | $4.35 | $3.95 |
| Resistance Level | $5.69 | $4.75 |
| Average True Range (ATR) | 0.47 | 0.18 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 6.49 | 73.53 |
Price Performance
Historical ComparisonAbout DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.